Pliant Therapeutics (Pliant Therapeutics) EBIT per Share : $-2.84 (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Pliant Therapeutics EBIT per Share?

Pliant Therapeutics's EBIT per Share for the three months ended in Mar. 2024 was $-0.77. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.84.

During the past 3 years, the average EBIT per Share Growth Rate was -17.10% per year. During the past 5 years, the average EBIT per Share Growth Rate was -53.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Pliant Therapeutics's EBIT per Share or its related term are showing as below:

PLRX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -282.7 Med: -17.1 Max: -13.3
Current: -17.1

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Pliant Therapeutics was -13.30% per year. The lowest was -282.70% per year. And the median was -17.10% per year.

PLRX's 3-Year EBIT Growth Rate is ranked worse than
72.57% of 1305 companies
in the Biotechnology industry
Industry Median: 3.6 vs PLRX: -17.10

Pliant Therapeutics's EBIT for the three months ended in Mar. 2024 was $-46.51 Mil.

Pliant Therapeutics EBIT per Share Historical Data

The historical data trend for Pliant Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pliant Therapeutics EBIT per Share Chart

Pliant Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.05

-1.95

-2.71

-2.92

-2.73

Pliant Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.66	-0.69	-0.69	-0.68	-0.77

Pliant Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Pliant Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-160.069	/	58.719
=	-2.73

Pliant Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-46.51	/	60.181
=	-0.77

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.84

Pliant Therapeutics (NAS:PLRX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Pliant Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Pliant Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Pliant Therapeutics (Pliant Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pliant Therapeutics Inc (NAS:PLRX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

9PT:Germany

Address

260 Littlefield Avenue, South San Francisco, CA, USA, 94080

Website

https://www.pliantrx.com

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Executives

Hans Hull	officer: Chief Business Officer	C/O AVALANCHE BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Eric Lefebvre	officer: Chief Medical Officer	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Keith Lamont Cummings	officer: Chief Financial Officer	C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Bernard Coulie	director, officer: President and CEO	C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Mike Ouimette	officer: General Counsel	C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Thomas A Mccourt	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Darren S Cline	director	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Lily Cheung	officer: Chief Human Resource Officer	260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Katharine Knobil	director	C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421
Pyott David E I	director	C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612
Third Rock Ventures Gp Iv, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Kevin P Starr	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Smital Shah	director	C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Suzanne Louise Bruhn	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Redmile Group, Llc	10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129